Skip to main content
. 2017 Nov 6;7:263. doi: 10.3389/fonc.2017.00263

Figure 3.

Figure 3

Targeted treatment of preleukemic mutations may be context dependent. In chronic phase CML, treatment with imatinib efficiently targets heamtopoietic progenitor cells (HPCs) but does not target HSCs, likely due to context specificity.